mProX™ Human CTLA4 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CTLA4 Stable Cell Line (S01YF-1023-PY167). Click the button above to contact us or submit your feedback about this product.
Jordan Miller (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Peyton Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The antitumor effect of siPD-1 and siCTLA-4 in the H22 allograft.
The study assessed the antitumor efficacy of siRNA targeting PD-1 and CTLA-4 in H22 allograft-bearing mice, with CT as the control group. The experimental groups included siPD-1, siCTLA-4, and siPD-1+siCTLA-4. A photograph displayed four representative tumor-bearing mice, each representing one of the groups, taken 30 days post H22 cell inoculation. Additionally, images depicted five solid tumors harvested from each group at the same time point. Tumor volume progression was tracked through a tumor diameter change curve, measured every 4 days over 30 days using a caliper, as outlined in the section describing the assessment of the H22 mice's physiological state.
Ref: Liang, Leilei, et al. "The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice." Cellular & Molecular Biology Letters 23 (2018): 1-11.
Pubmed: 30564277
DOI: 10.1186/s11658-018-0122-0
Research Highlights
Sabini, Elena. et al. "Сytotoxic T lymphocyte-associated protein-4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas." Endocrine-related cancer, 2023.
CTLA4 is a protein typically expressed on the surface of T lymphocytes and serves as a negative regulator. It is targeted by immunotherapy in patients with various types of cancer. In this study, the expression of CTLA4 in the pituitary gland was investigated to provide further reasoning for the use of immune checkpoint inhibitors in pituitary adenoma patients who do not respond to conventional treatments. 157 human pituitary gland specimens were analyzed, including 50 normal glands and 107 adenomas of various types. Results showed that CTLA4 expression was detectable in most normal glands and was significantly higher in pituitary adenomas. Prolactin- and growth hormone-secreting adenomas displayed the highest levels of CTLA4. These findings suggest the potential of using immune checkpoint inhibitors in pituitary adenoma treatment.
Sabini, Elena. et al. "Сytotoxic T lymphocyte-associated protein-4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas." Endocrine-related cancer, 2023.
Pubmed:
37870923
DOI:
10.1530/ERC-23-0196
Wang, Le. et al. "Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in Ovarian Cancer." Analytical cellular pathology (Amsterdam), 2023.
Ovarian cancer (OC) is a major contributor to gynecological cancer-related mortality and is ranked as the fifth leading cause of cancer-related death among women in the United States. The regulation of programmed cell death has been identified as a crucial factor in both tumor development and the effectiveness of immunotherapy in cancer treatment.
Wang, Le. et al. "Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in Ovarian Cancer." Analytical cellular pathology (Amsterdam), 2023.
Pubmed:
37868825
DOI:
10.1155/2023/7365503
